(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/189278 A1

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 9/20* (2006.01)

(21) International Application Number:
PCT/EP2022/055519

(22) International Filing Date:
04 March 2022 (04.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21161493.8 09 March 2021 (09.03.2021) EP

(71) Applicant: **BAYER AKTIENGESELLSCHAFT** [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).

(72) Inventors: **WIESWEG-MERKEL, Susanne**; Lilienstraße 19e, 42719 Solingen (DE). **SERNO, Peter**; Offenbachstr.12, 51467 Bergisch Gladbach (DE).

(74) Agent: **BIP PATENTS**; Alfred-Nobel-Straße 10, 40789 Monheim am Rhein (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

WO 2022/189278 A1

(54) **Title:** PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-2[4]-CHLORO-4-ETHYL-7[3]-FLUORO-3[5]-METHOXY-3[2],5- DIOXO-1[4]-(TRIFLUOROMETHYL)-3[2]H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-7[4]-CARBOXAMIDE

Figure 1:



(57) **Abstract:** The present invention relates to amorphous solid dispersions (ASD) and solid pharmaceutical dosage forms for oral administration comprising (4S)-2[4]-chloro-4-ethyl-7[3]-fluoro-3[5]-methoxy-3[2],5-5 dioxo-1[4]-(trifluoromethyl)-3[2]H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptaphane-7[4]-carboxamide (active ingredient (I)), characterized in that the active ingredient (I) is immediately released from the amorphous solid dispersions (ASD) and the solid pharmaceutical dosage forms for oral administration, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*